Vertex Pharmaceuticals
VRTX
1,222 hedge funds and large institutions have $68B invested in Vertex Pharmaceuticals in 2022 Q4 according to their latest regulatory filings, with 186 funds opening new positions, 435 increasing their positions, 440 reducing their positions, and 64 closing their positions.
191% more first-time investments, than exits
New positions opened: 186 | Existing positions closed: 64
9% more funds holding
Funds holding: 1,124 → 1,222 (+98)
8% more call options, than puts
Call options by funds: $420M | Put options by funds: $390M
0.72% less ownership
Funds ownership: 93.07% → 92.35% (-0.72%)
1% less capital invested
Capital invested by funds: $68.6B → $68B (-$591M)
1% less repeat investments, than reductions
Existing positions increased: 435 | Existing positions reduced: 440
30% less funds holding in top 10
Funds holding in top 10: 40 → 28 (-12)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$195M |
| 2 |
JP Morgan Chase
New York
|
+$192M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
+$152M |
| 4 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
+$132M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$126M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Janus Henderson Group
London,
United Kingdom
|
-$493M |
| 2 |
Canada Pension Plan Investment Board
Toronto Ontario,
Ontario, Canada
|
-$404M |
| 3 |
Wellington Management Group
Boston,
Massachusetts
|
-$366M |
| 4 |
BlackRock
New York
|
-$305M |
| 5 |
Lazard Asset Management
New York
|
-$147M |
VRTX Hedge Fund Activity: Q4 2022 in Review
1,222 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in Vertex Pharmaceuticals (VRTX) for Q4 2022, worth a combined $68B — down 0.86% from $68.6B a quarter earlier.
Buyers outnumbered sellers: 186 funds opened new VRTX positions and 64 closed out — a net gain of 122 holders — while 435 added to existing stakes and 440 trimmed.
The largest buyer was Morgan Stanley, adding an estimated $195M. The largest seller was Janus Henderson Group, cutting an estimated $493M.
- 1,222 institutional investors held Vertex Pharmaceuticals (VRTX) as of Q4 2022, up from 1,124 in Q3 2022.
- Funds reported $68B of Vertex Pharmaceuticals stock for Q4 2022, down 0.86% quarter-over-quarter.
- 186 funds opened new Vertex Pharmaceuticals positions in Q4 2022 and 64 closed out, a net change of +122 holders.
- The largest Vertex Pharmaceuticals buyer in Q4 2022 was Morgan Stanley, an estimated $195M added.
- The largest Vertex Pharmaceuticals seller in Q4 2022 was Janus Henderson Group, an estimated $493M sold.
Based on aggregated 13F filings for Q4 2022.